Please use this identifier to cite or link to this item: http://223.31.159.10:8080/jspui/handle/123456789/1126
Title: Structure-based drug repurposing to inhibit the DNA gyrase of Mycobacterium tuberculosis
Authors: Balasubramani, G. L.
Rajput, Rinky
Gupta, Manish
Dahiya, Pradeep
Thakur, Jitendra K.
Bhatnagar, Rakesh
Grover, Abhinav
Keywords: ATP hydrolysis
ATPase
DNA gyrase
DNA supercoiling
drug repurposing
Mycobacterium tuberculosis
Issue Date: 2020
Publisher: Portland Press
Citation: Biochemical Journal, 477(21): 4167–4190
Abstract: Drug repurposing is an alternative avenue for identifying new drugs to treat tuberculosis (TB). Despite the broad-range of anti-tubercular drugs, the emergence of multi-drug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis (Mtb) H37Rv, as well as the significant death toll globally, necessitates the development of new and effective drugs to treat TB. In this study, we have employed a drug repurposing approach to address this drug resistance problem by screening the drugbank database to identify novel inhibitors of the Mtb target enzyme, DNA gyrase. The compounds were screened against the ATPase domain of the gyrase B subunit (MtbGyrB47), and the docking results showed that echinacoside, doxorubicin, epirubicin, and idarubicin possess high binding affinities against MtbGyrB47. Comprehensive assessment using fluorescence spectroscopy, surface plasmon resonance spectroscopy (SPR), and circular dichroism (CD) titration studies revealed echinacoside as a potent binder of MtbGyrB47. Furthermore, ATPase, and DNA supercoiling assays exhibited an IC50 values of 2.1–4.7 µM for echinacoside, doxorubicin, epirubicin, and idarubicin. Among these compounds, the least MIC90 of 6.3 and 12 μM were observed for epirubicin and echinacoside, respectively, against Mtb. Our findings indicate that echinacoside and epirubicin targets mycobacterial DNA gyrase, inhibit its catalytic cycle, and retard mycobacterium growth. Further, these compounds exhibit potential scaffolds for optimizing novel anti-mycobacterial agents that can act on drug-resistant strains.
Description: Accepted date: October 08 2020
Gov't Doc #: https://portlandpress.com/biochemj/article-abstract/477/21/4167/226605/Structure-based-drug-repurposing-to-inhibit-the?redirectedFrom=fulltext
URI: http://223.31.159.10:8080/jspui/handle/123456789/1126
ISSN: 1470-8728
Appears in Collections:Institutional Publications

Files in This Item:
File Description SizeFormat 
Thakur JK_2020_5.pdf
  Restricted Access
3.84 MBAdobe PDFView/Open Request a copy


Items in IR@NIPGR are protected by copyright, with all rights reserved, unless otherwise indicated.